Blinatumomab, initially designated MT-103, embodies a novel bispecific protein, engineered to directly target CD19 on leukemic B cells while simultaneously binding to CD3 on peripheral lymphocytes. The dual engagement induces antibody-dependent cellular killing, effectively triggering T cell-medi

Belimumab, referred to as LymphoStat β, represents a groundbreaking approach for autoimmune diseases, particularly systemic lupus erythematosus. This drug inhibits B lymphocyte stimulator, a critical protein involved in lymphocyte production and harmful formation. By reducing BAFF levels, LymphoS